FY2027 EPS Estimate for Pharming Group Lifted by Analyst

Key Points

• HC Wainwright raised its FY2027 EPS estimate for Pharming Group to $0.56 from $0.54, maintaining a “Buy” rating and a $37 price target.
• Pharming reported quarterly EPS of $0.02, missing the $0.06 consensus estimate by $0.04. Analyst sentiment is mixed, resulting in a consensus “Hold” rating and an average target price of $38.67.
• PHAR shares were reported up 10.6%, opening at $10.67, while MAC Alpha Capital Management disclosed a new 2.15 million-share stake valued at approximately $29.8 million.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Investment analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for shares of Pharming Group in a research note issued on Thursday, October 22nd. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $0.56 for the year, up from their previous forecast of $0.54. HC Wainwright has a "Buy" rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group's current full-year earnings is $0.22 per share.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%.

Several other research firms have also issued reports on PHAR. Oppenheimer reaffirmed an "outperform" rating on shares of Pharming Group in a research note on Thursday, July 30th. Canaccord Genuity Group set a $38.00 target price on shares of Pharming Group in a research note on Wednesday, September 23rd. Zacks Research lowered Pharming Group from a "hold" rating to a "strong sell" rating in a research note on Friday, July 31st. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Pharming Group in a research note on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $38.67.

Pharming Group Trading Up 10.6%

PHAR stock opened at $10.67 on Friday. The firm has a fifty day moving average price of $10.68 and a 200 day moving average price of $12.63. Pharming Group has a fifty-two week low of $9.11 and a fifty-two week high of $21.34. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01. The firm has a market cap of $755.22 million, a PE ratio of 88.92 and a beta of -0.05.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP acquired a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,148,144 shares of the company's stock, valued at approximately $29,838,000. Pharming Group comprises about 6.0% of MAC Alpha Capital Management LP's investment portfolio, making the stock its 2nd biggest position. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent SEC filing. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming's principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.